Multi-omics Analysis of the Biomarkers and Molecular Mechanism of Rheumatoid Arthritis With Bone Destruction

Qian Huang
Department of Clinical Research Center, Dazhou Central Hospital

Jiang Su
Barnsley Hospital Rheumatology Department

Weihua Zhang
Department of Rheumatology, Dazhou Central Hospital

Shengjia Chang
Shantou University Medical College

Silin Li
Department of Clinical Research Center, Dazhou Central Hospital

Jun Zhou
Department of Clinical Research Center

Jie Zhang
Department of Clinical Research Center

Xue Li
Joint Clinical Research Center

Tingting Wang
Department of Rheumatology, Dazhou Central Hospital

Xuejun Jiang
Department of Rheumatology, Dazhou central hospital

Jianhong Wu
Department of Rheumatology, Dazhou Central Hospital

Jing Zhu
Department of Rheumatology, Sichuan Provincial people Hospital

Fanxin Zeng (zengfx@pku.edu.cn)
Department of Clinical Research Center, Dazhou Central Hospital

Research article

Keywords: Biomarkers, Molecular Mechanism, Rheumatoid Arthritis
Abstract

Objectives

Our study aimed to elucidate the role of metabolites, bacteria, and fungi in rheumatoid arthritis (RA) patients with bone destruction (BD(+)) and find some biomarkers to predicate bone progression of RA.

Methods

We conducted plasma metabolites of the 127 RA patients and 69 healthy control by using nontargeted liquid chromatography-mass spectrometry (LC-MS), and the gut bacteria and fungi were assessed by 16S rRNA and internal transcribed spacer (ITS).

Results

Compared with RA patients without bone destruction (BD(-)), some metabolites, bacteria, and fungi altered in BD(+). Several metabolites were selected as key metabolites for classifying the BD(+) and BD(-) groups with moderate accuracy (AUC=0.71). Metabolites-groups, metabolites-metabolites, and metabolites-clinical factors had a certain correlation, and 7 metabolites were enriched in glycerophospholipid metabolism and L-arginine and proline metabolism pathways. The bacteria and fungi of the BD(+) group showed significant differences in composition and function compared with BD(-) group. The changed 4 bacteria and 12 fungi yielded accuracy (AUC=0.74 and AUC=0.87, respectively) for the two groups. Taken 7 metabolites, 4 bacteria and 12 fungi as a panel for AUC analysis, an improved AUC of 0.99 significantly discriminated the two groups. The changed metabolites, gut bacteria, and fungi may affected the pathway related to L-arginine.

Conclusions

Our nontargeted LC-MS, 16S rRNA, and ITS highlight a novel link among the metabolites, bacteria, fungi, and pathology of BD(+), which contributed to our understanding of the role of metabolites, bacteria, and fungi in BD(+) aetiology and offers some novel biomarkers to predict the bone progression of RA.

Introduction

Rheumatoid arthritis (RA) is a systemic disease mediated by autoimmunity and characterized by inflammatory manifestations of the joints and synovitis, as well as bone destruction caused by joint injury, cartilage destruction and osteoclast activation, which eventually leads to the destruction and even deformity of bone, cartilage and tendon [1-3]. In recent years, the research of metabolites and intestinal microbes has surpassed genetic factors and the environmental triggers in RA bone destruction (BD(+) ), but the involved mechanisms of among metabolites, bacteria, and fungi is stilling unknown.

Metabolism is a general term for a series of ordered chemical reactions that take place in living organisms to maintain life [4] and is indispensable for the maintenance of life [5]. At present,
metabolomics is an effective tool to identify biomarkers of RA and other diseases, Hiroshi Furukawa et al. have proved that metabolomic profiling will be useful for discovering candidate screening biomarkers for interstitial lung disease in RA [6], Lun Zhang et al. successfully identified and validated a simple, high-performing, metabolite-based test for detecting early stage (I/II) non-small cell lung cancer patients in plasma [7].

In recent years, balancing the human gut microbes has been used as a powerful tool in the treatment of a variety of diseases [8-10]. Increasing evidence has shown that the composition and function of intestinal bacteria are closely related to autoimmune diseases [11]. Studies have demonstrated that intestinal flora imbalances can lead to the occurrence and deterioration of RA and a series of rheumatic diseases, Toshihiro Kishikawa et al. have proved that microbiome plays a important role in RA aetiology. Deshire Alpizar-Rodriguez also certificated that Prevotella spp. enrichment in individuals in pre-clinical stages of RA, before the onset of RA, suggests a role of intestinal dysbiosis in the development of RA [12].

Fungi in the gastrointestinal tract are now recognized as a significant part of the gut microbes, and they may play an important role in human health [13]. Although there are many studies on fungi in humans [14-17], in contrast to bacteria, the characteristics of the fungi in the gastrointestinal tract of RA patients has never been described, and there is little knowledge about the fungus in the gastrointestinal tract of RA patients with bone destruction.

As far as we know, there is no any study reported a mechanism driving the imbalance of bone metabolism involving differences in metabolites, bacteria and fungi in RA patients. In our study, a systematic study was used to expound the role of the changed metabolites, bacteria, and fungi in bone destruction and the related mechanisms during the pathogenesis of BD(+).

Materials And Methods

Participant recruitment

Our study was approved by the Dazhou Central Hospital (Ethical review number: IRB-022). The participants in this study included BD(+), BD(-), and HC. The patients with RA in this study were diagnosed according to the 2010 American College of Rheumatology (ACR)-European League Against Rheumatism (EULAR) classification criteria. They were recruited from the Department of Rheumatology and Immunology, Dazhou Central Hospital, from November, 2017 to July, 2020. Two senior radiologists reviewed the X-ray films of both the hands and wrists of the same patient to determine whether there was bone destruction. If the judgments were inconsistent, another senior radiologist made the final decision after reviewing the film again. Sixty-nine HC were recruited from the Department of Physical Examination at Dazhou Central Hospital in July, 2020. Finally, a total of 127 RA patients, including 91 BD(+), 36 BD(-), and 69 HC were considered for this analysis and had sufficient plasma for metabolomics analysis. Fecal samples of 50 BD(+) and 23 BD(-) were used to analyze gut bacteria and fungi by 16S rRNA and ITS sequencing (Fig. S1), and the participants’ characteristics are shown in Table S1.
**Plasma and fecal sample collection**

Each participant’s whole blood was centrifuged at 3,500 rpm/min for 10 minutes first, and the supernatant was moved to an enzyme-free 1.5-ml EP tube and centrifuged in a high-speed centrifuge at 12,000 rpm/min for 10 minutes. Then, the supernatants (plasma) was moved to another enzyme-free 1.5-ml EP tube, frozen rapidly in liquid nitrogen, and stored at -80°C until extraction. The fecal samples were divided into 200 mg sections, frozen rapidly in liquid nitrogen, and then stored at -80°C until extraction.

**Nontargeted LC-MS/MS**

A UHPLC (1290 Infinity LC, Agilent Technologies) coupled to a quadrupole time-of-flight (AB Sciex TripleTOF 6600) was used for HILIC separation, and all samples were analyzed by using a 2.1-mm × 100-mm ACQUITY UPLC BEH 1.7-μm column (Waters, Ireland).

**Pathway Enrichment Analysis**

The significant enrichment in KEGG pathways among the chosen metabolics was analyzed by MetaboAnalyst 4.0 (https://www.metaboanalyst.ca/).

**Fecal sample DNA extraction and Illumina MiSeq sequencing**

According to the manufacturer's protocol, total DNA was extracted from fecal samples. All DNA samples were quality checked, and the concentration was quantified by NanoDrop 2000 spectrophotometers (Thermo Fisher Scientific, Wilmington, DE, USA). Bacterial 16S rRNA gene fragments (V3-V4) were amplified from the extracted DNA using the primers 338F ACTCCTACGGGAGGCAGCAG and 806R GGACTACHVGGGTWTCTAAT, and fungal ITS gene fragments (V3-V4) were amplified from the extracted DNA using the primers ITS1F CTTGGTCATTTAGAGGAAGTAA and ITS2R GCTGCGTTCTTCATCGATGC.

**Statistical analysis**

The processed data were analyzed by Pareto-scaled principal component analysis (PCA) and orthogonal partial least-squares discriminant analysis (OPLS-DA). The variable importance in the projection (VIP) value of each variable in the OPLS-DA model was calculated to indicate its contribution to the classification. Metabolites with a VIP value >1 was further included in a Student's t-test at the univariate level to measure the significance of each metabolite. The differentiation performance of selected classifiers to distinguish the BD(+) and BD(-) groups was quantified using receiver operating characteristic (ROC) curve analysis. DADA2-denoised sequences are usually called amplicon sequence variants (ASVs). The taxonomic assignment of ASVs was performed using the Naive Bayes consensus taxonomy classifier implemented in QIIME 2 and the SILVA 16S rRNA database (v138). ASV analysis, community diversity analysis, species diversity analysis, model predictive analysis and Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt2) function prediction analysis for the 16S rRNA bacteria and the ITS fungi sequencing data were performed using the free online platform microbiomeanalyst (https://www.microbiomeanalyst.ca/). All tests were performed using...
GraphPad Prism (v5.0) (GraphPad Software, Inc., CA, USA), SPSS Statistics (V.24.0.0.0) (SPSS Inc., Chicago, USA) or R software (Version 3.4.4).

Results

Nontargeted LC-MS/MS and correction analysis

In this study, a total of 404 metabolites were identified among the BD(+), BD(-), and HC groups. Unsupervised PCA revealed some degree of separation between the metabolites of RA and HC, indicating that there was a difference in metabolic profiles between RA and HC. However, the PCA results revealed that it was difficult to separate the BD(+) and BD(-) groups (Fig. 1A, B). Seven metabolites were selected based on the VIP (VIP > 1) and P-value (P < 0.1) as key metabolites for classifying the BD(+) and BD(-) groups (Table 1). The heatmap analysis results of the relative intensity of metabolite showed that 6 downregulated metabolites negatively and 1 upregulated metabolite positively correlated with BD(+) group (Fig. 1C). The results of Spearman correlation analysis, which was used to identify potential metabolite-metabolite correlations, showed that 6 metabolites had a correlation (Fig. 1D). The correlations between the relative content of metabolites and clinical factors were analyzed, and the results shown that there were negative correlations among the three metabolites, L-arginine, 1-Oleoyl-sn-glycero-3-phosphocholine, and glycerophosphocholine, and Disease Activity Score 28-joint count erythrocyte sedimentation rate (DAS28-ESR), interleukin 6 (IL6), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) (Fig. 1E) and the statistical analysis, among 7 metabolites, IL6, ESR, and CRP, was shown in Table S2.

Enrichment of altered metabolites and functional analysis

Pathway analysis of the 5 identified metabolites revealed significant enrichment in two pathways, including glycerophospholipid metabolism and L-arginine and proline metabolism (Fig. 2A). A schematic diagram of the L-arginine and proline metabolism signaling pathway is shown in Fig. 2B, this pathway is related to L-arginine and creatine. Different levels of L-arginine and creatine were observed among the BD(+), BD(-) and HC groups (Fig. 2C-D). A schematic diagram of the glycerophospholipid metabolism signaling pathway is shown in Fig. 3E; this pathway is related to 1-Oleoyl-sn-glycero-3-phosphocholine, choline and glycerophosphocholine. Different levels of 1-Oleoyl-sn-glycero-3-phosphocholine, choline and glycerophosphocholine were observed among the three groups (Fig. 2F-H).

Alterations in bacterial composition in RA patients based on 16S rRNA data and bacteria-based prediction

In order to visualize the overall community structure of gut bacteria among fecal samples, Principal co-ordinates analysis (PCoA) was applied to visualize the overall community structure of gut microflora among all fecal samples on the ASV level. There was no significant difference between the BD(+) and BD(-) groups based on PCoA at the ASV level (Fig. S2A, R²=0.011, P=0.788). Moreover, the rank abundance curve was analyzed, which reflected the richness and evenness of the species. These results suggested that although some genera differed in their abundance rank, the community composition was
largely concordant between the two groups (Fig. S2B). A Venn diagram displayed 62 unique bacteria in the BD(+) group, 17 unique bacteria in the BD(-) group and 177 bacteria shared by both groups based on the genus level (Fig. 3A). Community diversity analysis was used to analyze the percent of community abundance of the two groups at the genus level. The results showed that these bacteria have subtle differences between the two groups (Fig. 3B). To explore the specific bacterial taxa characterized in the two groups, linear discriminant analysis (LDA, score >2) effect size (LEfSe) analysis was applied. The results showed that 10 bacteria were significantly changed, and *Morganella* levels was more abundant in the BD(-) group, while other bacteria were more abundant in the BD(+) group (Fig. 3C, D). Then, the result of the Wilcoxon rank-sum test bar plot at the genus level showed that 8 bacteria were significantly different between the two groups (Fig. 3E). To test whether potential diagnostic biomarkers can be used to predict BD(+), we developed a random forest model based on the bacteria. Finally, the optimized model utilized 12 bacteria, which provided the best discriminatory power (AUC=0.74) (Fig. 3F and Fig. S2C). Thus, the prediction model showed a high discriminatory power to predict the RA status. We predicted corresponding changes in modules and pathways using PICRUSt2 between the two groups. PICRUSt2 analysis suggested that these changes in the relative ASV abundance may be associated with the upregulation of pathways involving tetracycline biosynthesis; the mTOR signaling pathway; caffeine metabolism (Fig. 3G); and the regulation of modules involving polyamine biosynthesis, arginine = ornithine =..., F420 biosynthesis, cholesterol biosynthesis, squalene 2,3-epoxide =,..., cationic antimicrobial peptide (CAMP) resistance and the NADH dehydrogenase (ubiquinone) 1 alpha subcomplex (Fig. 4H).

**Analysis of the fungi in the BD(+) and BD(-) groups**

ITS was used to analyze the differences between the BD(+) and BD(-) groups. First, alpha diversity was used to obtain information about the abundance and diversity of species in the fecal samples, and the results showed that Shannon, Shannoneven, Simpson, and SimpsonEven indexes were significant difference between two groups (P < 0.05), while the Ace, Chao, and Sobs indexes were not different between two groups (P > 0.05) (Fig. 4A). Rank abundance curves evaluated relative fungi evenness, the result showed that all samples were similar patterns (Fig. S3A). To measure the extent of the similarity of the fungal macrobiotics, non-metric multidimensional scaling (NMDS) at the genus level was used to test the homogeneity of dispersion among different groups. Our results demonstrated that there was a significant difference between the two groups (Fig. 4B, $R^2=0.036$, P=0.027). The composition of these fungi has subtle differences between the two groups, and largely made up of *Candida, Aspergillus,* and *Debaryomyces* (Fig. 4C). Moreover, the Venn diagram showed that 212 fungi were shared between the two groups, and 86 fungi were unique for the BD(-) group and 165 fungi were unique for the BD(+) group on the genus level (Fig. S3B). To identify fungal taxa that differed in relative abundances between the two groups, LEfSe analysis was performed. The results showed that there were some significantly differential fungi according to the following criteria: LDA score > 2 and P-value cutoff < 0.05 (Fig. 4D and Fig. S3C ). The result of a Wilcoxon rank-sum test bar plot on the genus level also showed that 25 fungi had significant differences between the BD(+) and BD(-) groups, the top 15 fungi are shown
in Fig. 4E. Then, random forest was used to select the important characteristic fungi. Finally, the optimal model utilized 20 fungi, which provided the best discriminatory power (AUC=0.83) (Fig. 4F and Fig. S3D). To assess the potential functional changes in the fungi, we predicted the abundance of pathways and enzymes using PICRUSt2 and compared the differences between the BD(+) and BD(-) groups. We found that the BD(+) group was associated with some pathways, including significant upregulation of L-proline biosynthesis II (from arginine) (Fig. 4G), and 2 enzymes (NAD(+)-protein-arginine ADP-ribosyltransferase and arginine kinase) were related to arginine (Fig. 5H).

**The correction of metabolites, bacteria and fungi between the BD(+) and BD(-) groups and AUC analysis**

To explore the potential relationships among the metabolites, gut bacteria and fungi, the Spearman rank correlation coefficient was used to evaluate the correlation among the metabolites, gut bacteria and fungi. Combined with the previous analysis, we focused on the relationship between L-arginine and others. The results showed a strong positive correlation between L-arginine and glycerophosphocholine, and a strong negative correlation between L-arginine and 1-oleoyl-sn-glycero-3-phosphocholine, choline, *Roussoella, Hannaella, Debaryomyces* (P < 0.05) (Fig. 5A). To further observe the predictive effect of metabolites, bacteria, and fungi on BD(+), we used the 7 identified metabolites as a panel, and the AUC was 0.71. Based on LEfSe, Wilcoxon rank sum test and random forest model analysis, we respectively selected 4 bacteria or 12 fungi as the research objects for AUC analysis, and the AUC were 0.74 and 0.85. Finally, 7 metabolites, 4 bacteria, and 12 fungi were combined as a panel for analysis, and an improved AUC of 0.99 significantly enhanced the power to discriminate between the two groups (Fig. 5B). Together, these results show that the changed of 7 metabolites, 4 bacteria, and 12 fungi has a certain ability to predict bone destruction in RA patients.

**Discussion**

With the rapid development of technology, microbiology and metabolomics have progressed greatly, and they have been widely used in various studies [18-21]. Microbial gene sequencing methods or metabolomics cannot directly clarify the mechanism of disease occurrence and development, and they also cannot be used alone to identify which members of the gut microbiota affect the host and other key problems. The disadvantages of single-omics studies have emerged, while the advantages of multi-omics studies have gradually become clear. The purpose of this study was to elucidate the role of metabolites, bacteria, and fungi in BD(+) pathology and find some biomarkers to predicate bone progression of RA. At present, although there are many studies on patients with rheumatoid bone destruction [22-24], only few studies have examined changes in metabolism or changes in intestinal bacteria in patients with bone destruction.

In our study, three novel metabolites were used to describe the metabolic profile, gut bacteria and fungi change spectrum in the BD(+) group. Although nontargeted metabolomics and bacterial analyses did not clearly discriminate the BD(+) and BD(-) groups, some metabolites and gut microbiota changed in patients, which suggested that disrupts biochemical homeostasis may lead bone destruction. In our
study, pathway analysis revealed that 7 dysregulated metabolites were potentially related to the metabolic pathways of arginine and proline metabolism and glycerophospholipid metabolism, at the same time, the changed gut bacteria, and fungi may affected the pathway related to L-arginine. Some studies have indicated that L-arginine and proline have effects on inflammation [25-27], and these research results are consistent with our experimental results.

After analyzing the relationships between the identified metabolites and clinical parameters, we concluded that three metabolites, 1-Oleoyl-sn-glycero-3-phosphocholine, glycerophosphocholine and L-arginine, related to the severity of RA patients might represent a panel of potential small molecule biomarkers for assessing the severity of RA patient. Julia S. Brunner found that L-arginine plays an extremely important role in the process of bone destruction in RA and concluded that a high content of L-arginine promotes bone destruction in patients with RA based on animal experiments [28]. Interestingly, in our study, we found that RA patients had a higher content of L-arginine than HC, but when we compared the content of L-arginine between the BD(+) and BD(-) groups, we found that the BD(+) group had a lower content of L-arginine. This may be because L-arginine was consumed excessively in the process of bone destruction, so the content of L-arginine was reduced.

Glycerophospholipids can be hydrolyzed to produce lysophospholipids (LPs). LP was initially regarded as a common intermediate in the synthesis of phospholipids. However, later studies showed that LP exhibits biological characteristics similar to extracellular growth factors or signaling molecules [29-31]. Some studies have shown that important LPs, including lysophosphatidylcholine (LPC), lysophosphatidic acid (LPA) and certain sphingomyelins, can participate in disease processes, such as atherosclerosis, vascular dementia, and spinal cord injury, by activating the PPARγ pathway [32-34]. At present, a large number of studies have proven that there is a clear correlation between glycerophospholipids and inflammation [35-37]. In our study, the glycerophospholipid signaling pathway was changed in BD(+) patients, which showed that the glycerophospholipid signaling pathway plays an important role in the process of bone destruction. The results of this experiment are consistent with those of other previous studies, which proves that our experimental results have a certain degree of reliability.

LEfSe bar analysis, the Wilcoxon rank-sum test and random forest analysis were used to compare the changes in intestinal bacteria and fungi between the BD(+) and BD(-) groups. Finally, 4 species of bacteria and 12 fungi were selected as markers to predict the progress of bone destruction. AUC analysis was used to analyze the metabolites, bacteria and fungi of single or combined changes to distinguish the BD(+) and BD(-) groups. These results showed that the AUC of 7 metabolites was 0.71, the AUC of 4 bacteria was 0.74, the AUC of 12 fungi was 0.87, and the combined AUC was 0.99, which suggested that the combination of metabolites, bacteria and fungi was more effective for the evaluation of bone destruction of RA.

When studying the potential relationships among metabolites, bacteria and fungi, we found that there were positive and negative correlations among metabolites, bacteria and fungi. After reviewing previous
studies, we focused on the relationship between arginine and metabolites, microbes and fungi. The results proved that the metabolites choline and 1-Oleoyl-sn-glycero-3-phosphocholine were negatively correlated and glycerophosphocholine was positively correlated with L-arginine, and the fungi Debaryomyces, Hannaella, and Roussoella were negatively correlated with L-arginine. However, when examining the relationship between L-arginine and bacteria, we found no obvious correlation.

Combined analysis of the changed pathways among the three omics’ analyses revealed a common pathway involving L-arginine. These results indicate that L-arginine plays an important role in the BD(+) group, but the specific mechanism by which metabolites, bacteria and fungi affect the L-arginine pathway is not clear. We should perform further research on the mechanism of L-arginine-related pathways in subsequent experiments.

Conclusions

Collectively, our nontargeted LC-MS/MS, 16S rRNA and ITS analysis study of RA patients suggests some disrupted metabolites, bacteria and fungi form a distinct functional profile in RA patients with bone damage. This study is the first step in assessing the bone progression of RA patients by using metabolic and microbiological methods. It also has some certain limitations. First, because our study cohort did not include a validation cohort, it was impossible to accurately determine the prognostic value of the identified potential metabolic biomarkers for bone progression in RA patients. Subsequently, since there were no plasma or fecal samples from RA patients before bone destruction in this study, we were unable to examine the changes in the concentrations of metabolites, bacteria and fungi over time, which may be predictive of disease progression, treatment response or clinical outcome. In addition, we did not perform cell-based experiments or animal experiments to clarify the specific role of the identified metabolites, bacteria and fungi in the BD(+) group. Therefore, we need to conduct a large-scale external cohort study to verify the utility of the identified potential biomarkers and basic experiments to clarify the specific role of the identified metabolites, bacteria and fungi in the BD(+) group. The objective is to perform multi-omics analysis and study the mechanism of the occurrence and development of BD(+) and provide new treatment ideas and methods for the clinical treatment of RA patients.

Abbreviations

RA: rheumatoid arthritis; BD(+) : RA patients with bone destruction; BD(-) : RA patients without bone destruction; LC-MS: liquid chromatography-mass spectrometry; ITS: internal transcribed spacer; ACR: American College of Rheumatology; EULAR : European League Against Rheumatism; PCA: principal component analysis; OPLS-DA : orthogonal partial least-squares discriminant analysis; VIP: variable importance in the projection; ROC: receiver operating characteristic; AUC: area under curve; ASVs: amplicon sequence variants; PICRUSt2: Phylogenetic Investigation of Communities by Reconstruction of Unobserved States; DAS28-ESR: Disease Activity Score 28-joint count erythrocyte sedimentation rate; IL6: interleukin 6; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; PCoA: Principal co-ordinates analysis; LDA: linear discriminant analysis; LEfSe: linear discriminant analysis effect size; NMDS: non-
metric multidimensional scaling; LPs: lysophospholipids; LPC: lysophosphatidylcholine; LPA: lysophosphatidic acid.

Declarations

Ethical Approval and Consent to participate

All patients were fully informed about the study and its aim, and our study was approved by the Dazhou Central Hospital (Ethical review number: IRB-022).

Consent for publication

Not applicable

Availability of supporting data

All data are available on request to the authors.

Competing interests: The authors declare that they have no competing financial interests.

Funding: This study was approved by Science and Technology of Sichuan Province (2021YFS0165) and Sichuan Province Medical Research Project (S20001).

Authors' contributions: Fanxin Zeng, Jing Zhu and Jianhong Wu designed the study. Qian Huang, Jiang Su and Weihua Zhang did the statistical analysis. Qian Huang and Shengjia Chang wrote the manuscript. Silin Li, Jun Zhou and Xue Li revised the manuscript. Jie Zhang, Tingting Wang, and Xuejun Jiang collected the samples. All authors reviewed the manuscript and approved the final draft.

Acknowledgements: We thank the Department of Rheumatology and Immunology, Dazhou Central Hospital and the participants of our study. We also thank Huanhuan Xie, Weihua Jiang, Tingting Wang, Xinyue Wei, Xianda Xie for plasma and fecal samples collection.

Author information

1Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, Sichuan, China.

2Department of Rheumatology, Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.

3Department of Rheumatology, Dazhou Central Hospital, Dazhou, Sichuan, China.

4Shantou University Medical College, Shantou University, Guangdong, China

*These authors contribute equally.

References
1. Adam S, Simon N, Steffen U, Andes FT, Scholtyssek C, Muller DIH, Weidner D, Andreev D, Kleyer A, Culemann S et al: *JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function*. *Sci Transl Med* 2020, 12(530).

2. Sparks JA: *Rheumatoid Arthritis*. *Ann Intern Med* 2019, 170(1):ITC1-ITC16.

3. England BR, Thiele GM, Anderson DR, Mikuls TR: *Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications*. *BMJ* 2018, 361:k1036.

4. Judge A, Dodd MS: *Metabolism*. *Essays Biochem* 2020, 64(4):607-647.

5. Nicholson JK, Lindon JC: *Systems biology: Metabonomics*. *Nature* 2008, 455(7216):1054-1056.

6. Furukawa H, Oka S, Shimada K, Okamoto A, Hashimoto A, Komiy A, Saisho K, Yoshikawa N, Katayama M, Matsui T et al: *Serum Metabolomic Profiling in Rheumatoid Arthritis Patients With Interstitial Lung Disease: A Case-Control Study*. *Front Med (Lausanne)* 2020, 7:599794.

7. Zhang L, Zheng J, Ahmed R, Huang G, Reid J, Mandal R, Maksymuik A, Sitar DS, Tappia PS, Ramjiawan B et al: *A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection*. *Cancers (Basel)* 2020, 12(3).

8. Litvak Y, Byndloss MX, Baumler AJ: *Colonocyte metabolism shapes the gut microbiota*. *Science* 2018, 362(6418).

9. Sahay B, Ge Y, Colliou N, Zadeh M, Weiner C, Mila A, Owen JL, Mohamadzadeh M: *Advancing the use of Lactobacillus acidophilus surface layer protein A for the treatment of intestinal disorders in humans*. *Gut Microbes* 2015, 6(6):392-397.

10. Chen Y, Yang B, Ross RP, Jin Y, Stanton C, Zhao J, Zhang H, Chen W: *Orally Administered CLA Ameliorates DSS-Induced Colitis in Mice via Intestinal Barrier Improvement, Oxidative Stress Reduction, and Inflammatory Cytokine and Gut Microbiota Modulation*. *J Agric Food Chem* 2019, 67(48):13282-13298.

11. Jiao Y, Wu L, Huntington ND, Zhang X: *Crosstalk Between Gut Microbiota and Innate Immunity and Its Implication in Autoimmune Diseases*. *Front Immunol* 2020, 11:282.

12. Alpizar-Rodriguez D, Lesker TR, Gronow A, Gilbert B, Raemy E, Lamacchia C, Gabay C, Finckh A, Strowig T: *Prevotella copri in individuals at risk for rheumatoid arthritis*. *Ann Rheum Dis* 2019, 78(5):590-593.

13. Schei K, Avershina E, Oien T, Rudi K, Follestad T, Salamati S, Odegard RA: *Early gut mycobiota and mother-offspring transfer*. *Microbiome* 2017, 5(1):107.
14. Wilson D, Deepe GS, Jr.: The intersection of host and fungus through the zinc lens. *Curr Opin Microbiol* 2019, 52:35-40.

15. Muraosa Y, Toyotome T, Yahiro M, Kamei K: Characterisation of novel-cell-wall LysM-domain proteins LdpA and LdpB from the human pathogenic fungus *Aspergillus fumigatus*. *Sci Rep* 2019, 9(1):3345.

16. Ferling I, Dunn JD, Ferling A, Soldati T, Hillmann F: Conidial Melanin of the Human-Pathogenic Fungus *Aspergillus fumigatus* Disrupts Cell Autonomous Defenses in Amoebae. *mBio* 2020, 11(3).

17. Stewart DB, Sr., Wright JR, Fowler M, McLimans CJ, Tokarev V, Amaniera I, Baker O, Wong HT, Brabec J, Drucker R *et al.*: Integrated Meta-omics Reveals a Fungus-Associated Bacteriome and Distinct Functional Pathways in Clostridioides difficile Infection. *mSphere* 2019, 4(4).

18. Asnicar F, Berry SE, Valdes AM, Nguyen LH, Piccinno G, Drew DA, Leeming E, Gibson R, Le Roy C, Khatib HA *et al.*: Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals. *Nat Med* 2021, 27(2):321-332.

19. Basolo A, Hohenadel M, Ang QY, Piaggi P, Heinitz S, Walter M, Walter P, Parrington S, Trinidad DD, von Schwartzzenberg RJ *et al.*: Effects of underfeeding and oral vancomycin on gut microbiome and nutrient absorption in humans. *Nat Med* 2020, 26(4):589-598.

20. Wang Z, Bergeron N, Levison BS, Li XS, Chiu S, Jia X, Koeth RA, Li L, Wu Y, Tang WHW *et al.*: Impact of chronic dietary red meat, white meat, or non-meat protein on trimethylamine N-oxide metabolism and renal excretion in healthy men and women. *Eur Heart J* 2019, 40(7):583-594.

21. Edinburgh RM, Bradley HE, Abdullah NF, Robinson SL, Chrzanowski-Smith OJ, Walhin JP, Joanisse S, Manolopoulos KN, Philp A, Hengist A *et al.*: Lipid Metabolism Links Nutrient-Exercise Timing to Insulin Sensitivity in Men Classified as Overweight or Obese. *J Clin Endocrinol Metab* 2020, 105(3).

22. Croft AP, Campos J, Jansen K, Turner JD, Marshall J, Attar M, Savary L, Wehmeyer C, Naylor AJ, Kemble S *et al.*: Distinct fibroblast subsets drive inflammation and damage in arthritis. *Nature* 2019, 570(7760):246-251.

23. Baker JF, Conaghan PG, Emery P, Baker DG, Ostergaard M: Relationship of patient-reported outcomes with MRI measures in rheumatoid arthritis. *Ann Rheum Dis* 2017, 76(3):486-490.

24. Pan H, Guo R, Ju Y, Wang Q, Zhu J, Xie Y, Zheng Y, Li T, Liu Z, Lu L *et al.*: A single bacterium restores the microbiome dysbiosis to protect bones from destruction in a rat model of rheumatoid arthritis. *Microbiome* 2019, 7(1):107.

25. Roda MA, Xu X, Abdalla TH, Sadik M, Szul T, Bratcher PE, Viera L, Solomon GM, Wells JM, McNicholas CM *et al.*: Proline-Glycine-Proline Peptides Are Critical in the Development of Smoke-induced Emphysema. *Am J Respir Cell Mol Biol* 2019, 61(5):560-566.
26. Wei P, Hao L, Thomas S, Buchberger AR, Steinke L, Marker PC, Ricke WA, Li L: Urinary Amine Metabolomics Characterization with Custom 12-Plex Isobaric DiLeu Labeling. *J Am Soc Mass Spectrom* 2020, **31**(9):1854-1860.

27. Wang S, Yang X: Eleutheroside E decreases oxidative stress and NF-kappaB activation and reprograms the metabolic response against hypoxia-reoxygenation injury in H9c2 cells. *Int Immunopharmacol* 2020, **84**:106513.

28. Brunner JS, Vulliard L, Hofmann M, Kieler M, Lercher A, Vogel A, Russier M, Bruggenthies JB, Kerndl M, Saferding V et al: Environmental arginine controls multinuclear giant cell metabolism and formation. *Nat Commun* 2020, **11**(1):431.

29. Han X, Sun S, Sun Y, Song Q, Zhu J, Song N, Chen M, Sun T, Xia M, Ding J et al: Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease. *Autophagy* 2019, **15**(11):1860-1881.

30. Zhao J, Bi W, Xiao S, Lan X, Cheng X, Zhang J, Lu D, Wei W, Wang Y, Li H et al: Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice. *Sci Rep* 2019, **9**(1):5790.

31. Peng J, Li J, Huang J, Xu P, Huang H, Liu Y, Yu L, Yang Y, Zhou B, Jiang H et al: p300/CBP inhibitor A-485 alleviates acute liver injury by regulating macrophage activation and polarization. *Theranostics* 2019, **9**(26):8344-8361.

32. Hayakawa S, Matsushima T, Kimura T, Minato H, Katagiri K: Zygosporin A, a new antibiotic from *Zygosporium masonnii*. *J Antibiotor* (Tokyo) 1968, **21**(8):523-524.

33. Qiao Y, Liu L, Yin L, Xu L, Tang Z, Qi Y, Mao Z, Zhao Y, Ma X, Peng J: FABP4 contributes to renal interstitial fibrosis via mediating inflammation and lipid metabolism. *Cell Death Dis* 2019, **10**(6):382.

34. Liddle DM, Kavanagh ME, Wright AJ, Robinson LE: Apple Flavonols Mitigate Adipocyte Inflammation and Promote Angiogenic Factors in LPS- and Cobalt Chloride-Stimulated Adipocytes, in Part by a Peroxisome Proliferator-Activated Receptor-gamma-Dependent Mechanism. *Nutrients* 2020, **12**(5).

35. Giannakis N, Sansbury BE, Patsalos A, Hays TT, Riley CO, Han X, Spite M, Nagy L: Dynamic changes to lipid mediators support transitions among macrophage subtypes during muscle regeneration. *Nat Immunol* 2019, **20**(5):626-636.

36. Sato H, Taketomi Y, Miki Y, Murase R, Yamamoto K, Murakami M: Secreted Phospholipase PLA2G2D Contributes to Metabolic Health by Mobilizing omega3 Polyunsaturated Fatty Acids in WAT. *Cell Rep* 2020, **31**(5):107579.

37. Nakamura N, Pence LM, Cao Z, Beger RD: Distinct lipid signatures are identified in the plasma of rats with chronic inflammation induced by estradiol benzoate and sex hormones. *Metabolomics* 2020, **16**(9):95.
Table

Due to technical limitations, table 1 is only available as a download in the Supplemental Files section.

Figures

Figure 1
Metabolite analysis of serum sample among HC, BD(+) and BD(-) groups. A. PCA analysis of anion metabolites. B. PCA analysis of cation metabolites. C. Expression of differential metabolites in BD(+) group and BD(-) group. D. The correlation analysis of differential metabolites. E. The correlation analysis between metabolites and clinical factors. * 0.01 < P ≤ 0.05, ** 0.001 < P ≤ 0.01. HC: healthy control. BD(+): RA patients with bone destruction. BD(-): RA patients without bone destruction. PCA: Pareto-scaled principal component analysis.
Analysis of seven differential metabolite enrichment pathways. A. Enrichment of differential metabolites. B. Arginine and proline metabolism pathways. C. L-Arginine content. D. Creatine content. E. Glycerophospholipid metabolism pathway. F. 1-Oleoyl-sn-glycero-3-phosphocholine content. G. Glycerophosphocholine content. H. Choline content. * $0.01 < P \leq 0.05$, ** $0.001 < P \leq 0.01$, *** $P < 0.001$, NS, not significant.

Figure 3
Various methods were used to analyze the bacterial on genus level between BD(+) and BD(-) groups. A. Venn analysis. B. Community barplot analysis. C. LDA analysis results (LDA>2). D. The cladogram analyzed LEfSe. E. Wilcoxon rank-sum test. F. Random Forest analysis. G. Function prediction. * 0.01 < P ≤ 0.05, ** 0.001 < P ≤ 0.01, *** P < 0.001. BD(+): RA patients with bone destruction. BD(-): RA patients without bone destruction. LDA: Linear Discriminant Analysis.

Figure 4
Various methods analyzed the difference fungal microbiota on genus level between BD(+) and BD(-) groups. A. Boxplot of alpha diversity, characterized by the shannon, simpson, simpsoneven and shannoneven index. B. β-diversity analysis of bacterial microbiota. C. Fungi composition of two groups. C. The cladogram analyzed LEfSe of the fungi. E. Wilcoxon rank-sum test. F. Random Forest analysis. G. The changed pathways of two groups were predicted by PICRUSt2. H. The enzymes and related arginine were predicted by PICRUSt2. * 0.01 < P ≤ 0.05, ** 0.001 < P ≤ 0.01. *** P < 0.001. BD(+): RA patients with bone destruction. BD(-): RA patients without bone destruction. PICRUSt2: Phylogenetic Investigation of Communities by Reconstruction of Unobserved States
Figure 5

Correction and receiver operating characteristic (ROC) analysis. A. The correlation analysis of the differences among metabolites, bacterial and fungi. B. ROC analysis of metabolites, bacterial, and fungi alone or in combination to distinguish for the BD(+) and BD(-) groups. * 0.01 < P ≤ 0.05, ** P < 0.01. BD(+): RA patients with bone destruction. BD(-): RA patients without bone destruction. ROC: Receiver operating characteristic.
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- TableS1.pdf
- TableS2.pdf
- Table1.pdf
- FigureS1copy.jpg
- FigureS2copy.jpg
- FigureS3copy.jpg
- Supplementarymaterials.docx